Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Novel IDH1-Targeted Glioma Therapies.

Karpel-Massler G, Nguyen TTT, Shang E, Siegelin MD.

CNS Drugs. 2019 Dec;33(12):1155-1166. doi: 10.1007/s40263-019-00684-6.

PMID:
31768950
2.

Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.

Fathi AT, Nahed BV, Wander SA, Iafrate AJ, Borger DR, Hu R, Thabet A, Cahill DP, Perry AM, Joseph CP, Muzikansky A, Chi AS.

Oncologist. 2016 Feb;21(2):214-9. doi: 10.1634/theoncologist.2015-0342. Epub 2016 Feb 1.

3.

IDH mutations in cancer and progress toward development of targeted therapeutics.

Dang L, Yen K, Attar EC.

Ann Oncol. 2016 Apr;27(4):599-608. doi: 10.1093/annonc/mdw013. Review.

4.

Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics.

Golub D, Iyengar N, Dogra S, Wong T, Bready D, Tang K, Modrek AS, Placantonakis DG.

Front Oncol. 2019 May 17;9:417. doi: 10.3389/fonc.2019.00417. eCollection 2019. Review.

5.

Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer.

Sharma H.

Curr Top Med Chem. 2018;18(6):505-524. doi: 10.2174/1568026618666180518091144. Review.

PMID:
29773061
6.

Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.

Upadhyay VA, Brunner AM, Fathi AT.

Pharmacol Ther. 2017 Sep;177:123-128. doi: 10.1016/j.pharmthera.2017.03.003. Epub 2017 Mar 14. Review.

PMID:
28315358
7.

IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.

Zhang C, Moore LM, Li X, Yung WK, Zhang W.

Neuro Oncol. 2013 Sep;15(9):1114-26. doi: 10.1093/neuonc/not087. Epub 2013 Jul 21. Review.

8.

Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.

Han CH, Batchelor TT.

Chin Clin Oncol. 2017 Jun;6(3):33. doi: 10.21037/cco.2017.06.11.

9.

ML309: A potent inhibitor of R132H mutant IDH1 capable of reducing 2-hydroxyglutarate production in U87 MG glioblastoma cells.

Davis M, Pragani R, Popovici-Muller J, Gross S, Thorne N, Salituro F, Fantin V, Straley K, Su M, Dang L, Simeonov A, Shen M, Boxer MB.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2012 Apr 16 [updated 2013 May 8].

10.

Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.

Chotirat S, Thongnoppakhun W, Promsuwicha O, Boonthimat C, Auewarakul CU.

J Hematol Oncol. 2012 Mar 7;5:5. doi: 10.1186/1756-8722-5-5.

11.

Comprehensive Metabolomic Analysis of IDH1R132H Clinical Glioma Samples Reveals Suppression of β-oxidation Due to Carnitine Deficiency.

Miyata S, Tominaga K, Sakashita E, Urabe M, Onuki Y, Gomi A, Yamaguchi T, Mieno M, Mizukami H, Kume A, Ozawa K, Watanabe E, Kawai K, Endo H.

Sci Rep. 2019 Jul 5;9(1):9787. doi: 10.1038/s41598-019-46217-5.

12.

Targeting isocitrate dehydrogenase (IDH) in cancer.

Fujii T, Khawaja MR, DiNardo CD, Atkins JT, Janku F.

Discov Med. 2016 May;21(117):373-80. Review.

13.

Consequences of IDH1/2 Mutations in Gliomas and an Assessment of Inhibitors Targeting Mutated IDH Proteins.

Kaminska B, Czapski B, Guzik R, Król SK, Gielniewski B.

Molecules. 2019 Mar 9;24(5). pii: E968. doi: 10.3390/molecules24050968. Review.

14.

Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.

Wakimoto H, Tanaka S, Curry WT, Loebel F, Zhao D, Tateishi K, Chen J, Klofas LK, Lelic N, Kim JC, Dias-Santagata D, Ellisen LW, Borger DR, Fendt SM, Vander Heiden MG, Batchelor TT, Iafrate AJ, Cahill DP, Chi AS.

Clin Cancer Res. 2014 Jun 1;20(11):2898-909. doi: 10.1158/1078-0432.CCR-13-3052. Epub 2014 Apr 8.

15.

IDH mutations in glioma and acute myeloid leukemia.

Dang L, Jin S, Su SM.

Trends Mol Med. 2010 Sep;16(9):387-97. doi: 10.1016/j.molmed.2010.07.002. Epub 2010 Aug 5. Review.

PMID:
20692206
16.

Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.

Turcan S, Fabius AW, Borodovsky A, Pedraza A, Brennan C, Huse J, Viale A, Riggins GJ, Chan TA.

Oncotarget. 2013 Oct;4(10):1729-36.

17.

Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.

Intlekofer AM, Shih AH, Wang B, Nazir A, Rustenburg AS, Albanese SK, Patel M, Famulare C, Correa FM, Takemoto N, Durani V, Liu H, Taylor J, Farnoud N, Papaemmanuil E, Cross JR, Tallman MS, Arcila ME, Roshal M, Petsko GA, Wu B, Choe S, Konteatis ZD, Biller SA, Chodera JD, Thompson CB, Levine RL, Stein EM.

Nature. 2018 Jul;559(7712):125-129. doi: 10.1038/s41586-018-0251-7. Epub 2018 Jun 27.

18.

Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.

Houdova Megova M, Drábek J, Dwight Z, Trojanec R, Koudeláková V, Vrbková J, Kalita O, Mlcochova S, Rabcanova M, Hajdúch M.

Klin Onkol. Fall 2017;30(5):361-371. doi: 10.14735/amko2017361.

PMID:
29031038
19.

IDH1 and IDH2 mutations in gliomas.

Cohen AL, Holmen SL, Colman H.

Curr Neurol Neurosci Rep. 2013 May;13(5):345. doi: 10.1007/s11910-013-0345-4. Review.

20.

Determining IDH-Mutational Status in Gliomas Using IDH1-R132H Antibody and Polymerase Chain Reaction.

Gondim DD, Gener MA, Curless KL, Cohen-Gadol AA, Hattab EM, Cheng L.

Appl Immunohistochem Mol Morphol. 2019 Nov/Dec;27(10):722-725. doi: 10.1097/PAI.0000000000000702.

PMID:
30358614

Supplemental Content

Support Center